Amylyx Pharmaceuticals (AMLX) Equity Average (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) has 5 years of Equity Average data on record, last reported at $318.6 million in Q4 2025.
- For Q4 2025, Equity Average rose 76.54% year-over-year to $318.6 million; the TTM value through Dec 2025 reached $318.6 million, up 76.54%, while the annual FY2025 figure was $235.0 million, 21.43% down from the prior year.
- Equity Average reached $318.6 million in Q4 2025 per AMLX's latest filing, up from $249.9 million in the prior quarter.
- Across five years, Equity Average topped out at $425.9 million in Q4 2023 and bottomed at -$137.6 million in Q4 2021.
- Average Equity Average over 5 years is $204.9 million, with a median of $228.8 million recorded in 2024.
- Peak YoY movement for Equity Average: soared 672.19% in 2023, then crashed 57.62% in 2024.
- A 5-year view of Equity Average shows it stood at -$137.6 million in 2021, then soared by 276.08% to $242.3 million in 2022, then skyrocketed by 75.77% to $425.9 million in 2023, then plummeted by 57.62% to $180.5 million in 2024, then soared by 76.54% to $318.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $318.6 million in Q4 2025, $249.9 million in Q3 2025, and $184.6 million in Q2 2025.